جزییات کتاب
This third volume in the successful 'Drug Discovery in Infectious Diseases' series is the first to deal with drug discovery in helminthic infections in human and animals. The result is a broad overview of different drug target evaluation methods, including specific examples of successful drug development against helminthes, and with a whole section devoted to vaccine development. With its well-balanced mix of high-profile contributors from academia and industry, this handbook and reference will appeal to a wide audience, including parasitologists, pharmaceutical industry, epidemiologists, and veterinary scientists.Content: Chapter 1 Ligand?Gated Ion Channels as Targets for Anthelmintic Drugs: Past, Current, and Future Perspectives (pages 1–21): Kristin Lees, Ann Sluder, Niroda Shannan, Lance Hammerland and David SattelleChapter 2 How Relevant is Caenorhabditis elegans as a Model for the Analysis of Parasitic Nematode Biology? (pages 23–41): Lindy Holden?Dye and Robert J. WalkerChapter 3 Integrating and Mining Helminth Genomes to Discover and Prioritize Novel Therapeutic Targets (pages 43–59): Dhanasekaran Shanmugam, Stuart A. Ralph, Santiago J. Carmona, Gregory J. Crowther, David S. Roos and Fernan AgueroChapter 4 Recent Progress in Transcriptomics of Key Gastrointestinal Nematodes of Animals – Fundamental Research Toward New Intervention Strategies (pages 61–72): Cinzia Cantacessi, Bronwyn E. Campbell, Aaron R. Jex, Ross S. Hall, Neil D. Young, Matthew J. Nolan and Robin B. GasserChapter 5 Harnessing Genomic Technologies to Explore the Molecular Biology of Liver Flukes?Major Implications for Fundamental and Applied Research (pages 73–87): Neil D. Young, Aaron R. Jex, Cinzia Cantacessi, Bronwyn E. Campbell and Robin B. GasserChapter 6 RNA Interference: A Potential Discovery Tool for Therapeutic Targets of Parasitic Nematodes (pages 89–103): Collette BrittonChapter 7 RNA Interference as a Tool for Drug Discovery in Parasitic Flatworms (pages 105–119): Akram A. Da'dara and Patrick J. SkellyChapter 8 Mechanism?Based Screening Strategies for Anthelmintic Discovery (pages 121–134): Timothy G. GearyChapter 9 Identification and Profiling of Nematicidal Compounds in Veterinary Parasitology (pages 135–157): Andreas Rohwer, Jurgen Lutz, Christophe Chassaing, Manfred Uphoff, Anja R. Heckeroth and Paul M. SelzerChapter 10 Quantitative High?Content Screening?Based Drug Discovery against Helmintic Diseases (pages 159–179): Rahul SinghChapter 11 Use of Rodent Models in the Discovery of Novel Anthelmintics (pages 181–199): Rebecca Fankhauser, Linsey R. Cozzie, Bakela Nare, Kerrie Powell, Ann E. Sluder and Lance G. HammerlandChapter 12 To Kill a Mocking Worm: Strategies to Improve Caenorhabditis elegans as a Model System for use in Anthelmintic Discovery (pages 201–216): Andrew R. Burns and Peter J. RoyChapter 13 Anthelmintic Drugs: Tools and Shortcuts for the Long Road from Discovery to Product (pages 217–232): Eugenio L. de Hostos and Tue NguyenChapter 14 Antinematodal Drugs – Modes of Action and Resistance: And Worms Will Not Come to Thee (Shakespeare: Cymbeline: IV, ii) (pages 233–249): Alan P. Robertson, Samuel K. Buxton, Sreekanth Puttachary, Sally M. Williamson, Adrian J. Wolstenholme, Cedric Neveu, Jacques Cabaret, Claude L. Charvet and Richard J. MartinChapter 15 Drugs and Targets to Perturb the Symbiosis of Wolbachia and Filarial Nematodes (pages 251–265): Mark J. Taylor, Louise Ford, Achim Hoerauf, Ken Pfarr, Jeremy M. Foster, Sanjay Kumar and Barton E. SlatkoChapter 16 Promise of Bacillus thuringiensis Crystal Proteins as Anthelmintics (pages 267–281): Yan Hu and Raffi V. AroianChapter 17 Monepantel: From Discovery to Mode of Action (pages 283–296): Ronald Kaminsky and Lucien RufenerChapter 18 Discovery, Mode of Action, and Commercialization of Derquantel (pages 297–307): Debra J. Woods, Steven J. Maeder, Alan P. Robertson, Richard J. Martin, Timothy G. Geary, David P. Thompson, Sandra S. Johnson and George A. ConderChapter 19 Praziquantel: Too Good to be Replaced? (pages 309–321): Livia Pica?Mattoccia and Donato CioliChapter 20 Drug Discovery for Trematodiases: Challenges and Progress (pages 323–339): Conor R. Caffrey, Jurg Utzinger and Jennifer KeiserChapter 21 Barefoot thru' the Valley of Darkness: Preclinical Development of a Human Hookworm Vaccine (pages 341–356): Jeffrey M. Bethony, Maria Victoria Periago and Amar R. JariwalaChapter 22 Vaccines Linked to Chemotherapy: A New Approach to Control Helminth Infections (pages 357–375): Sara Lustigman, James H. McKerrow and Maria Elena BottazziChapter 23 Antifilarial Vaccine Development: Present and Future Approaches (pages 377–398): Sara Lustigman, David Abraham and Thomas R. KleiChapter 24 Proteases as Vaccines Against Gastrointestinal Nematode Parasites of Sheep and Cattle (pages 399–420): David KnoxChapter 25 Schistosomiasis Vaccines – New Approaches to Antigen Discovery and Promising New Candidates (pages 421–433): Alex Loukas, Soraya Gaze, Mark Pearson, Denise Doolan, Philip Felgner, David Diemert, Donald P. McManus, Patrick Driguez and Jeffrey BethonyChapter 26 Sm14 Schistosoma mansoni Fatty Acid?Binding Protein: Molecular Basis for an Antihelminth Vaccine (pages 435–449): Miriam Tendler, Celso Raul Romero Ramos and Andrew J. G. SimpsonChapter 27 Mechanisms of Immune Modulation by Fasciola hepatica: Importance for Vaccine Development and for Novel Immunotherapeutics (pages 451–463): Mark W. Robinson, John P. Dalton, Sandra M. O'Neill and Sheila M. DonnellyChapter 28 Prospects for Immunoprophylaxis Against Fasciola hepatica (Liver Fluke) (pages 465–484): Terry W. Spithill, Carlos Carmona, David Piedrafita and Peter M. SmookerChapter 29 Vaccines Against Cestode Parasites (pages 485–503): Marshall W. Lightowlers, Charles G. Gauci, Abdul Jabbar and Cristian Alvarez